A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
NCT04486716
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
111
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsing Multiple Sclerosis
Interventions
DRUG:
Ofatumumab
Sponsor
Novartis Pharmaceuticals